Literature DB >> 22946714

Clinical benefits of ezetimibe use: is absence of proof, proof of absence?

Ioanna Gouni-Berthold, Dimitri P Mikhailidis, Manfredi Rizzo.   

Abstract

Mesh:

Substances:

Year:  2012        PMID: 22946714     DOI: 10.1517/14656566.2012.720974

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


× No keyword cloud information.
  4 in total

1.  Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo.

Authors:  Ioanna Gouni-Berthold; Heiner K Berthold; Joo Young Huh; Reena Berman; Nadine Spenrath; Wilhelm Krone; Christos S Mantzoros
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

Review 2.  Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases.

Authors:  Ekaterina A Ivanova; Veronika A Myasoedova; Alexandra A Melnichenko; Andrey V Grechko; Alexander N Orekhov
Journal:  Oxid Med Cell Longev       Date:  2017-05-07       Impact factor: 6.543

Review 3.  Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches.

Authors:  Dragana Nikolic; Niki Katsiki; Giuseppe Montalto; Esma R Isenovic; Dimitri P Mikhailidis; Manfredi Rizzo
Journal:  Nutrients       Date:  2013-03-18       Impact factor: 5.717

4.  Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS).

Authors:  D Devroey; R P Radermecker; B J Van der Schueren; B Torbeyns; R J Jaken
Journal:  Int J Clin Pract       Date:  2013-12-06       Impact factor: 2.503

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.